News

Class 3 obesity conferred the greatest risk of mortality, complications, and higher resource utilization in alcohol-associated hepatitis hospitalizations.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Dupilumab's approval marks the first new, targeted therapy for CSU in more than a decade and is the 7th indication for a disease with underlying type 2 inflammation.

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.

This interview in the latest issue of The Respiratory Report features Jamie Hook, MD, discussing research into targeting the lung and not the virus to treat influenza.

This interview in the latest issue of The Respiratory Report features Divay Chandra, MD, MSc, discussing lithium's potential enhancement of alveolar repair after injury.

This interview in the latest issue of The Respiratory Report features William Zhang, MD, discussing AM iron accumulation, which may contribute to the well-known phenomenon of AM dysfunction in COPD6.

This interview in the latest issue of The Respiratory Report features Peter Miller, MD, PhD, discussing the potential role of CH in developing COPD.

Jaime Hook, MD, from Mount Sinai's research aims to develop new therapeutic approaches for influenza lung infection that protect against fatal SA coinfection.

Divay Chandra, MD, MSc, University of Pittsburgh, is evaluating whether higher circulating lithium levels are associated with emphysema in a new study.

Peter Miller, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, is working to further uncover the role of clonal hematopoeisis in COPD.

Jennifer Soung, MD, joins The Medical Sisterhood to discuss her journey to launching LEADderm and how owning the podium has changed her career.

A phase 3 trial found the Viaskin peanut patch effective in desensitizing peanut-allergic children aged 1 – 3 years, regardless of asthma, atopic dermatitis, or other food allergies.

Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.

Results indicate that FDD should be accounted for when measuring ganglion cell inner plexiform layer (GCIPL) in eyes with glaucoma.

Once-daily orforglipron showed strong efficacy and safety, matching injectable GLP-1s for A1c reduction and weight loss in the ACHIEVE-1 trial.

If approved, aflibercept 8 mg would mark the first RVO treatment indicated for up to every 8-week dosing, halving the injection frequency of other anti-VEGF options.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

In a recent study, a diagnostic protocol of 1:10 intradermal tests and subcutaneous provocation showed high accuracy for diagnosing immediate-type anesthetic allergy in children.

Meta-analysis results showed patients with ZZ AATD had a greater risk of liver disease and liver cancer than patients in comparator cohorts.

Radhakrishnan describes a unique initiative in Pittsburgh promoting health equity and closing the gap in cardiovascular health disparities.

Revolutionizing Atopic Dermatitis 2025 Annual Meeting cochair Raj Chovatiya, MD, PhD, previews the upcoming meeting.

Mona Shahriari, MD, previews the upcoming Revolutionizing Atopic Dermatitis Annual Meeting being held in Nashville, TN from June 06-07.

A pair of experts discuss unmet needs and educational gaps related to atopic dermatitis.

A new study identified 6 distinct CRSwNP endotype clusters, revealing that patients with mixed type 1/3 inflammation experience faster polyp recurrence than those with type 2 inflammation.

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology's 2025 Scientific Sessions.

The FDA cleared the expanded indication for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.